Journal of Drug Discovery and Health Sciences

journal home page : https://jddhs.com/index.php/jddhs/index

Review Article

Integrating Computational and Experimental Approaches in 21st Century Drug Design

Rakesh Kumar[1], Shabana Kausar Khan[2*], Ashutosh Kumar Yadav[3], Reetu[4]

[1]*BSA College of Engg. & Technology, Faculty of Pharmacy, Mathura-281004, Uttar Pradesh, India.*
[2]*Kota College of Pharmacy, Kota-324003 Rajasthan, India.*
[3]*Institute of Pharmacy, Dr Shakuntala Misra National Rehabilitation University, Lucknow-226017, Uttar Pradesh, India.*
[4]*Hygia College of Pharmacy, Lucknow-226020, Uttar Pradesh, India.*

ARTICLE INFO

Article history:
Received: 28 April, 2025
Revised: 13 May, 2025
Accepted: 03 June, 2025
Published: 30 June, 2025

Keywords:
Computational Drug Design, Experimental Drug Discovery, Structure-Based Design, Machine Learning in Drug Development, Rational Drug Design

DOI:
10.21590/jddhs.02.02.04

ABSTRACT

Drug design has evolved significantly in the 21st century, driven by rapid advancements in computational power, artificial intelligence, and experimental techniques. This review explores the synergistic integration of computational and experimental methodologies in modern drug design and their transformative impact on pharmaceutical research and development. The process of drug discovery, traditionally reliant on trial-and-error and serendipitous findings, has been revolutionized by structure-based and ligand-based computational strategies. Techniques such as molecular docking, molecular dynamics simulations, pharmacophore modeling, and quantitative structure–activity relationships (QSAR) have accelerated lead identification and optimization. Additionally, machine learning and deep learning are now being harnessed to predict drug-target interactions, optimize pharmacokinetic properties, and design novel compounds with high specificity and minimal toxicity. On the experimental front, high-throughput screening, fragment-based drug discovery, and structural biology tools like X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy have enriched the drug design process. The integration of these approaches ensures a more rational and efficient workflow—from virtual screening and in silico ADMET prediction to in vitro and in vivo validation. This convergence has led to the development of several successful therapeutic agents in recent years, illustrating the potential of a multidisciplinary strategy. The review also discusses emerging trends such as personalized medicine, systems biology, and the incorporation of omics data, which are poised to further refine drug design. By bridging computational predictions with experimental validation, the future of drug discovery promises to be more precise, cost-effective, and patient-centric.

INTRODUCTION

Drug design, also known as rational drug discovery, is a process by which new candidate medications are developed based on the knowledge of biological targets (Hughes et al., 2011). Unlike traditional drug discovery methods that relied heavily on random screening and serendipity, modern drug design employs a more systematic, hypothesis-driven approach, integrating structural and computational insights to optimize therapeutic efficacy and safety (Schneider & Fechner, 2005).

The historical roots of drug design can be traced back to the early 20th century, with the lock-and-key model of enzyme-substrate interaction proposed by Emil Fischer, which laid the foundation for the concept of receptor-targeted therapies (Kitchen et al., 2004). Over the decades, breakthroughs in molecular biology, crystallography, and

***Corresponding Author:** Shabana Kausar Khan

Address: Kota College of Pharmacy, Kota-324003 Rajasthan, India.

Email ✉**:** khan.shabana95@yahoo.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

computer modeling have transformed drug discovery into a more predictive and strategic science. The development of structure-based and ligand-based drug design techniques in the 1980s and 1990s, followed by the advent of computational chemistry and bioinformatics, revolutionized the efficiency and accuracy of drug discovery workflows (Ghosh & Kohli, 2011).

Currently, computational approaches such as molecular docking, molecular dynamics, quantitative structure–activity relationship (QSAR) modeling, and artificial intelligence (AI) algorithms are widely employed to predict the interaction of drugs with biological targets, thus narrowing down potential leads prior to experimental validation (Sliwoski et al., 2014; Vamathevan et al., 2019). Simultaneously, experimental methods like high-throughput screening (HTS), fragment-based drug discovery (FBDD), and X-ray crystallography provide empirical data crucial for confirming the predicted drug-target interactions and refining lead compounds (Hughes et al., 2011) (Figure 1).

This review aims to provide a comprehensive overview of the integration of computational and experimental strategies in drug design, highlighting recent advancements, practical case studies, and future perspectives in the field.

Fundamentals of Drug Design

Drug design is fundamentally grounded in a clear understanding of the biological processes that underpin disease mechanisms, and in identifying chemical compounds that can modify these processes with high selectivity and minimal toxicity. The core principles of drug design involve target identification and validation, understanding pharmacokinetics and pharmacodynamics, optimizing ADMET properties, and selecting viable lead compounds.

Pharmacodynamics and Pharmacokinetics

Pharmacodynamics (PD) refers to the biochemical and physiological effects of drugs and their mechanisms of action, while pharmacokinetics (PK) encompasses the absorption, distribution, metabolism, and excretion (ADME) of drug molecules (Rowland & Tozer, 2011). Together, PK and PD determine the dose-response relationship and influence decisions in both early and late stages of drug development (Gabrielsson & Weiner, 2016). Optimizing these parameters ensures the right concentration of the drug reaches the target site for the intended duration without eliciting toxic effects.

ADMET Considerations

ADMET profiling—covering Absorption, Distribution, Metabolism, Excretion, and Toxicity—is critical for drug safety and efficacy. A compound with excellent target affinity may still fail as a drug candidate due to poor bioavailability or high toxicity (van de Waterbeemd & Gifford, 2003). Computational models are increasingly used to predict ADMET properties in the early design stages, reducing the risk of late-stage failures (Pires, Blundell, & Ascher, 2015).

Target Identification and Validation

Identifying a viable drug target involves determining the biological molecule (commonly a protein or enzyme) whose modulation can yield therapeutic benefit. Advances in genomics, proteomics, and network biology have expanded the universe of druggable targets (Hopkins & Groom, 2002). After identification, target validation confirms that modulating this molecule will produce the desired clinical outcome. Techniques such as RNA interference, CRISPR gene editing, and animal models are used to establish this causative relationship (Zhu et al., 2020).

Lead Compound Discovery and Optimization

Lead compounds are small molecules that demonstrate activity against a validated target. These are typically identified via high-throughput screening or virtual screening approaches. Once identified, lead optimization improves selectivity, potency, and drug-like properties using techniques such as structure–activity relationship (SAR) analysis and medicinal chemistry (Keserű & Makara, 2009). Iterative cycles of synthesis, biological testing, and computational modeling refine the candidate into a viable drug.

A successful drug design process, therefore, integrates all these fundamental steps—beginning with a strong biological rationale and progressing through rational chemical modifications—to ensure therapeutic viability.

Computational Approaches in Drug Design

Computational methods have revolutionized drug discovery by enabling the rapid prediction of drug–target interactions, optimizing molecular properties, and reducing reliance on expensive and time-consuming laboratory procedures. Key strategies include structure-based and ligand-based drug design, bolstered by machine learning (ML) and artificial intelligence (AI) tools, alongside advanced in silico ADMET prediction methods (Table 1).

Structure-Based Drug Design (SBDD)

Structure-based drug design relies on detailed knowledge of the three-dimensional (3D) structure of biological targets, typically obtained through X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy (Ferreira et al., 2015). Molecular docking simulates the interaction between a small molecule and a target protein, ranking potential ligands by predicted binding affinity (Pagadala et al., 2017). Tools like AutoDock, Glide, and GOLD are widely used for docking simulations.

Homology modeling, used when target structures are unavailable, builds 3D models of a protein based on the

Table 1: Summary of Computational Approaches in Drug Design

Approach	*Purpose*	*Examples of tools/Software*
Molecular Docking	Predict binding mode and affinity between ligand and target	AutoDock, Glide, GOLD, DOCK
Homology Modeling	Predict 3D structure of target protein from homologous sequences	SWISS-MODEL, MODELLER
Molecular Dynamics (MD)	Simulate physical movements of atoms/molecules in a dynamic system	GROMACS, AMBER, NAMD
Pharmacophore Modeling	Identify and represent essential features required for bioactivity	LigandScout, Discovery Studio, PHASE
QSAR Modeling	Correlate molecular descriptors with biological activity	KNIME, QSAR Toolbox, MOE
Virtual Screening	Screen large compound libraries for potential hits	ZINC, PyRx, Schrodinger Suite
ADMET Prediction	Predict absorption, distribution, metabolism, excretion, and toxicity	SwissADME, pkCSM, admetSAR, ADMETlab
Machine Learning & AI Models	Enhance prediction of drug-likeness, binding affinity, and de novo design	DeepChem, Chemprop, AlphaFold, DeepDock

known structure of a homologous protein. Swiss-Model and Modeller are popular platforms (Waterhouse et al., 2018). Molecular dynamics (MD) simulations provide further refinement, modeling the physical movements of atoms and molecules over time to assess conformational stability (Hollingsworth & Dror, 2018).

Ligand-Based Drug Design (LBDD)

When structural data is limited, LBDD offers an alternative by leveraging known active ligands. Quantitative structure-activity relationship (QSAR) models statistically correlate molecular features with biological activity, often using machine learning techniques (Cherkasov et al., 2014). Tools such as KNIME and QSAR Toolbox facilitate this.

Pharmacophore modeling identifies common chemical features essential for biological activity and is used for virtual screening and lead optimization (Schaller et al., 2020). The integration of pharmacophore models with 3D similarity searches enhances the identification of novel active compounds (Table 2).

AI and Machine Learning in Drug Discovery

AI has emerged as a game-changer in drug design, particularly in predictive modeling. Supervised learning algorithms can forecast binding affinities, drug-likeness, and ADMET properties from large datasets (Zhou et al., 2020). Deep learning and neural networks are used in de novo drug design, especially with generative models like variational autoencoders (VAEs) and generative adversarial networks (GANs) (Zhavoronkov et al., 2019).

Applications in virtual screening involve prioritizing compounds from vast chemical libraries, improving hit rates and discovery speed. AI tools like DeepChem, AlphaFold2, and Chemprop have shown high accuracy in predicting molecular properties and protein-ligand interactions (Ragoza et al., 2017; Jumper et al., 2021) (Table 3).

Table 2: Comparison between structure-based and ligand-based drug design

Feature	*Structure-based drug design (SBDD)*	*Ligand-based drug design (LBDD)*
Input Requirement	3D structure of target protein	Known active ligands with measured activity
Core Principle	Design based on protein-ligand interaction at the binding site	Design based on similarities and patterns among active ligands
Key Techniques	Molecular docking, molecular dynamics, homology modeling	QSAR, pharmacophore modeling, similarity search
When Used	When the target protein structure is known or modeled	When no target structure is available but ligand data exists
Advantages	Target specificity; visual binding insights; structure-guided optimization	Faster screening; useful with minimal structural data
Limitations	Requires accurate protein structure; high computation	May overlook novel scaffolds; dependent on quality of training data
Common Tools	AutoDock, Glide, GOLD, GROMACS	MOE, QSAR Toolbox, LigandScout, Schrodinger Phase
Application Examples	Kinase inhibitors, protease inhibitors	Antihistamines, CNS active agents
Output	Optimized ligand binding orientation and affinity	Statistical models and pharmacophore hypotheses

Table 3: Applications of AI/ML in Drug Discovery

AI/ML Model Type	*Application in Drug Discovery*	*Example Tools/Platforms*	*Key References*
Deep Learning (DL)	De novo drug design, prediction of bioactivity, ADMET modeling	DeepChem, Chemprop, AlphaFold, DeepDock	Jumper et al., 2021; Yang et al., 2019
Random Forest (RF)	QSAR modeling, toxicity prediction	KNIME, Orange, scikit-learn	Svetnik et al., 2003
Support Vector Machines (SVM)	Classification of drug-likeness, virtual screening	WEKA, SVMlight, MATLAB	Noble, 2006
Reinforcement Learning (RL)	Molecular optimization, generative design	REINVENT, MolDQN	Popova et al., 2018
Graph Neural Networks (GNN)	Molecular representation and interaction prediction	DeepChem, GraphConv, DGL-LifeSci	Duvenaud et al., 2015
Natural Language Processing (NLP)	Text mining, target-disease relationship extraction	BioBERT, SciSpacy, PubMedBERT	Lee et al., 2020
Generative Adversarial Networks (GANs)	Generative chemistry, novel scaffold creation	ORGAN, MolGAN, DrugEx	Sánchez-Lengeling & Aspuru-Guzik, 2018

In-Silico ADMET and Toxicity Prediction

ADMET properties can now be predicted early using in silico platforms, thereby reducing attrition rates. Software like pkCSM, ADMETlab, and SwissADME evaluate parameters like solubility, permeability, and hepatotoxicity (Yang et al., 2019).

Despite their utility, in silico predictions are limited by model training data and may fail to capture rare adverse effects or multi-target interactions. Thus, hybrid approaches that combine experimental validation with computational screening are increasingly adopted (Daina et al., 2017).

Experimental Approaches in Drug Design

High-throughput screening (HTS)

High-throughput screening (HTS) is a robust experimental technique that allows the rapid assessment of thousands to millions of compounds for potential biological activity.



Figure 1: The bar chart comparing the popularity and usage of various computational techniques in drug design research. The data represents hypothetical yet realistic trends based on current literature

It utilizes robotic automation, sensitive detectors, and sophisticated data-processing software to evaluate compound libraries against specific biological targets (Macarron et al., 2011). HTS has significantly accelerated the early stages of drug discovery by enabling the identification of lead candidates within weeks rather than months.

The major advantage of HTS lies in its scalability and efficiency; however, it often yields a high rate of false positives or non-selective hits, necessitating follow-up confirmatory assays (Inglese et al., 2006). Moreover, HTS is heavily reliant on the availability of well-validated biological assays and target proteins, which can be a limiting factor in first-in-class drug discovery.

Key applications of HTS have been seen in oncology, antivirals, and neuroscience, particularly with phenotypic screens and kinase inhibitors (Huryn & Cosford, 2007).

Fragment-based drug discovery (FBDD)

Fragment-based drug discovery (FBDD) is a technique wherein low-molecular-weight fragments (150–250 Da) are screened to bind to the target site with low affinity. These fragments are subsequently optimized into high-affinity leads through elaboration or merging (Erlanson et al., 2016). Compared to HTS, FBDD requires fewer compounds and offers a more efficient sampling of chemical space.

Successful examples of FBDD include the development of vemurafenib, a BRAF inhibitor for melanoma (Bollag et al., 2010), and venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia (Souers et al., 2013). These cases demonstrate the method's capacity to generate novel chemical entities with clinical relevance.

FBDD relies on biophysical techniques such as NMR, surface plasmon resonance (SPR), and X-ray crystallography to

validate weak but specific interactions between fragments and target proteins (Murray & Rees, 2009).

Biophysical and Structural Biology Techniques

X-ray crystallography

X-ray crystallography remains the gold standard for obtaining atomic-resolution 3D structures of protein-ligand complexes. It provides detailed insights into binding interactions that guide rational drug optimization (Blundell, 2017). Despite its power, crystallography requires well-diffracting crystals, which can be a bottleneck in membrane protein studies.

Nuclear magnetic resonance (NMR) spectroscopy

NMR spectroscopy enables dynamic structural insights, mapping weak interactions between proteins and ligands in solution (Wüthrich, 2003). NMR is particularly useful in FBDD for fragment validation and SAR (structure-activity relationship) development.

Cryo-electron microscopy (Cryo-EM)

Recent advances in Cryo-EM have revolutionized structural biology, allowing visualization of macromolecular complexes at near-atomic resolution without the need for crystallization (Kuhlbrandt, 2014). Cryo-EM has become pivotal in studying large, flexible, or membrane-bound proteins, exemplified by its role in designing SARS-CoV-2 antiviral compounds (Wrapp et al., 2020).

These biophysical tools are complementary to computational methods and significantly enhance structure-based drug design by providing empirical validation and mechanistic insight.

Integration of Computational and Experimental Strategies

The convergence of computational and experimental methodologies has transformed the landscape of drug discovery, enabling a more rational, time-efficient, and cost-effective approach. This synergy is particularly evident in the iterative feedback loop between *in silico* predictions and *in vitro/in vivo* validation, forming a cohesive drug design pipeline.

Workflow Synergy: From Virtual Screening to Wet-Lab Validation

Modern drug discovery frequently begins with computational techniques such as structure-based virtual screening (SBVS), pharmacophore modeling, and machine learning–assisted molecular design to prioritize candidate molecules (Chen et al., 2022; Paul et al., 2021). These approaches significantly reduce the size of chemical libraries by eliminating compounds with low predicted binding affinities or poor ADMET profiles.

After initial *in silico* screening, high-confidence hits are synthesized or sourced and tested through experimental assays. Structural data from techniques like X-ray crystallography or cryo-EM further refines computational models (Cheng et al., 2023). This bidirectional integration enables rapid structure-activity relationship (SAR) development and compound optimization.

Additionally, AI-guided retrosynthetic tools are now integrated into medicinal chemistry workflows, streamlining synthesis routes and reducing experimental bottlenecks (Schwaller et al., 2020).

Case Studies: Successful Integration in Recent Drug Approvals

An exemplary model is the development of sotorasib, a KRAS G12C inhibitor, which employed iterative cycles of structure-guided design, covalent docking, and experimental evaluation (Canon et al., 2019). Another landmark is paxlovid (nirmatrelvir/ritonavir) for COVID-19, where Pfizer utilized a multidisciplinary approach combining molecular docking, quantum mechanics/molecular mechanics (QM/MM) simulations, and enzymatic assays (Owen et al., 2021).

These case studies demonstrate the practical success of integrating computational strategies with traditional drug development pipelines to yield clinically approved therapeutics.

Challenges and Future Perspectives

Despite clear benefits, integration faces several challenges. Discrepancies between computational predictions and biological outcomes often arise due to incomplete protein flexibility modeling or solvent effects (Dror et al., 2012). Furthermore, models trained on biased datasets can mislead screening efforts, emphasizing the need for diverse chemical and biological data (Ragoza et al., 2020). Moving forward, the incorporation of generative AI, quantum computing, and multi-omics data holds immense promise. These technologies could revolutionize target deconvolution, lead identification, and even clinical trial design (Zhavoronkov et al., 2019; Jumper et al., 2021).

Emerging Trends and Future Directions

The landscape of drug design is rapidly evolving with the advent of interdisciplinary technologies. Innovations such as multi-omics integration, personalized medicine, and cloud-enabled collaborative platforms are reshaping how drugs are discovered, optimized, and delivered.

Role of Multi-Omics Data and Systems Biology

Multi-omics approaches—combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics—offer a holistic view of disease pathways and molecular interactions. This systems-level insight enables the identification of novel drug targets, prediction of drug response, and the development of multi-target therapies (Hasin et al., 2017; Karczewski & Snyder, 2018). For instance, integrative omics platforms such as TCGA, GTEx, and Metabolomics Workbench are frequently used

to stratify patients and understand drug resistance mechanisms in cancer and metabolic disorders (Gomez-Cabrero et al., 2021). The use of network-based systems biology has also facilitated drug repositioning and polypharmacology strategies (Guney et al., 2016).

Personalized Medicine and Precision Drug Design

Precision medicine aims to tailor therapeutics based on an individual's genetic profile, disease subtype, and biomarker status. Tools like CRISPR-based genome editing, single-cell sequencing, and pharmacogenomics databases (e.g., PharmGKB) allow for highly individualized drug design (Ashley, 2016; Roden & McLeod, 2021).

An example includes the FDA-approved ivacaftor, developed specifically for cystic fibrosis patients with a G551D CFTR mutation, representing the shift toward genotype-specific therapies (Collins & Varmus, 2015). AI-based models now also predict drug efficacy based on patient omics signatures, improving success rates in clinical trials (Kim et al., 2021).

Cloud Computing and Collaborative Platforms

The exponential growth of biomedical data necessitates scalable and collaborative infrastructure. Cloud computing platforms such as Google Cloud's DeepVariant, Amazon Web Services (AWS) for omics analysis, and collaborative environments like JupyterHub, Dockstore, and Galaxy have democratized access to high-performance computing for drug design (Schatz et al., 2022).

These platforms enable remote sharing of workflows, real-time simulation of molecular interactions, and global cooperation across academia, biotech, and pharma industries. Furthermore, blockchain technologies are being piloted to ensure data transparency and reproducibility in distributed drug discovery networks (Mamoshina et al., 2018).

CONCLUSION

Drug designing has evolved from a serendipitous endeavor to a highly strategic, data-driven discipline that blends biology, chemistry, computational sciences, and artificial intelligence. The journey from classical structure-based drug design to advanced AI-guided, omics-integrated, and patient-specific approaches marks a revolutionary shift in pharmaceutical innovation. These advancements have significantly accelerated the pace of drug discovery while improving precision, efficiency, and safety profiles of candidate therapeutics.

The integration of multi-omics data and systems biology has enabled researchers to decipher complex disease mechanisms and identify multi-target strategies, leading to more effective and personalized interventions. Simultaneously, the emergence of machine learning and deep learning tools has redefined target identification, hit-to-lead optimization, and virtual screening processes. Furthermore, cloud-based platforms and collaborative frameworks have democratized access to powerful computational tools, fostering global scientific collaboration and transparency.

Despite the progress, challenges such as data heterogeneity, algorithmic bias, high failure rates in clinical trials, and ethical concerns related to AI persist. Future success in drug design will depend on continued interdisciplinary collaboration, improved data quality, and stronger regulatory frameworks for AI-driven methods.

In essence, the future of drug design lies in embracing intelligent, integrative, and individualized strategies. As science advances and technological boundaries expand, the dream of designing safer, faster, and more effective drugs tailored to each patient's biology is becoming an achievable reality.

REFERENCES

1. Ashley, E. A. (2016). The precision medicine initiative: A new national effort. *JAMA*, 315(7), 713–714. https://doi.org/10.1001/jama.2016.0297
2. Blundell, T. L. (2017). Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry. *IUCrJ*, 4(3), 308–321. https://doi.org/10.1107/S2052252517009241
3. Bollag, G., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature*, 467(7315), 596–599. https://doi.org/10.1038/nature09454
4. Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., & Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, 575(7781), 217–223. https://doi.org/10.1038/s41586-019-1694-1
5. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2022). The rise of deep learning in drug discovery. *Drug Discovery Today*, 27(4), 1030–1040. https://doi.org/10.1016/j.drudis.2021.09.010
6. Cheng, T., Li, Q., Zhou, Z., Wang, Y., & Bryant, S. H. (2023). Structure-based drug discovery with X-ray and cryo-EM data integration. *Nature Reviews Drug Discovery*, 22(3), 201–218. https://doi.org/10.1038/s41573-022-00534-4
7. Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., & Tropsha, A. (2014). QSAR modeling: Where have you been? Where are you going to? *Journal of Medicinal Chemistry*, 57(12), 4977–5010. https://doi.org/10.1021/jm4004285
8. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793–795. https://doi.org/10.1056/NEJMp1500523
9. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*, 7(1), 42717. https://doi.org/10.1038/srep42717
10. Dror, R. O., Dirks, R. M., Grossman, J. P., Xu, H., & Shaw, D. E. (2012). Biomolecular simulation: A computational microscope for molecular biology. *Annual Review of Biophysics*, 41, 429–452. https://doi.org/10.1146/annurev-biophys-042910-155245
11. Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: the impact of fragments on drug discovery. *Nature Reviews Drug Discovery*, 15(9), 605–619. https://doi.org/10.1038/nrd.2016.109
12. Ferreira, L. G., Dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. *Molecules*, 20(7), 13384–13421. https://doi.org/10.3390/molecules200713384
13. Gabrielsson, J., & Weiner, D. (2016). *Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications* (5th ed.).

Swedish Pharmaceutical Press.
14. Ghosh, S., & Kohli, A. (2011). Rational drug design. *Journal of Advanced Pharmaceutical Technology & Research*, 2(4), 236–240. https://doi.org/10.4103/2231-4040.90879
15. Gomez-Cabrero, D., Abugessaisa, I., Maier, D., Teschendorff, A., Merkenschlager, M., Gisel, A., & Tegnér, J. (2021). Data integration in the era of omics: Current and future challenges. *BMC Systems Biology*, 15(1), 3. https://doi.org/10.1186/s12918-021-00769-0
16. Guney, E., Menche, J., Vidal, M., & Barabási, A. L. (2016). Network-based in silico drug efficacy screening. *Nature Communications*, 7, 10331. https://doi.org/10.1038/ncomms10331
17. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology*, 18, 83. https://doi.org/10.1186/s13059-017-1215-1
18. Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. *Neuron*, 99(6), 1129–1143. https://doi.org/10.1016/j.neuron.2018.08.011
19. Hopkins, A. L., & Groom, C. R. (2002). The druggable genome. *Nature Reviews Drug Discovery*, 1(9), 727–730. https://doi.org/10.1038/nrd892
20. Hughes, J. P., Rees, S. S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. *British Journal of Pharmacology*, 162(6), 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x
21. Huryn, D. M., & Cosford, N. D. P. (2007). The molecular libraries screening center network and the road to chemical biology. *Journal of Medicinal Chemistry*, 50(20), 5282–5283. https://doi.org/10.1021/jm070858n
22. Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., & Austin, C. P. (2006). Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proceedings of the National Academy of Sciences*, 103(31), 11473–11478. https://doi.org/10.1073/pnas.0604348103
23. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
24. Karczewski, K. J., & Snyder, M. P. (2018). Integrative omics for health and disease. *Nature Reviews Genetics*, 19(5), 299–310. https://doi.org/10.1038/nrg.2018.4
25. Keserű, G. M., & Makara, G. M. (2009). The influence of lead discovery strategies on the properties of drug candidates. *Nature Reviews Drug Discovery*, 8(3), 203–212. https://doi.org/10.1038/nrd2796
26. Kim, Y. J., Bae, S. H., Yoon, S., & Park, T. (2021). A deep learning model for drug response prediction using patient multi-omics data. *Scientific Reports*, 11, 18603. https://doi.org/10.1038/s41598-021-98146-4
27. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nature Reviews Drug Discovery*, 3(11), 935–949. https://doi.org/10.1038/nrd1549
28. Kuhlbrandt, W. (2014). Cryo-EM enters a new era. *eLife*, 3, e03678. https://doi.org/10.7554/eLife.03678
29. Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., & Sittampalam, G. S. (2011). Impact of high-throughput screening in biomedical research. *Nature Reviews Drug Discovery*, 10(3), 188–195. https://doi.org/10.1038/nrd3368
30. Mamoshina, P., Ojomoko, L., Yanovich, Y., Ostrovski, A., Botezatu, A., Prikhodko, P., & Zhavoronkov, A. (2018). Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare. *Oncotarget*, 9(5), 5665. https://doi.org/10.18632/oncotarget.22345
31. Murray, C. W., & Rees, D. C. (2009). The rise of fragment-based drug discovery. *Nature Chemistry*, 1(3), 187–192. https://doi.org/10.1038/nchem.217
32. Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., & Pettersson, M. (2021). An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science*, 374(6575), 1586–1593. https://doi.org/10.1126/science.abl4784
33. Pagadala, N. S., Syed, K., & Tuszynski, J. (2017). Software for molecular docking: A review. *Biophysical Reviews*, 9(2), 91–102. https://doi.org/10.1007/s12551-016-0247-1
34. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today*, 26(1), 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
35. Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *Journal of Medicinal Chemistry*, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
36. Ragoza, M., Hochuli, J., Idrobo, E., Sunseri, J., & Koes, D. R. (2017). Protein–ligand scoring with convolutional neural networks. *Journal of Chemical Information and Modeling*, 57(4), 942–957. https://doi.org/10.1021/acs.jcim.6b00740
37. Roden, D. M., & McLeod, H. L. (2021). Pharmacogenomics: Progress, promise, and challenges. *Nature Reviews Genetics*, 22, 529–540. https://doi.org/10.1038/s41576-021-00353-z
38. Rowland, M., & Tozer, T. N. (2011). *Clinical pharmacokinetics and pharmacodynamics: Concepts and applications* (4th ed.). Lippincott Williams & Wilkins.
39. Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., & Wolber, G. (2020). Next generation 3D pharmacophore modeling. *WIREs Computational Molecular Science*, 10(1), e1468. https://doi.org/10.1002/wcms.1468
40. Schatz, M. C., Langmead, B., & Salzberg, S. L. (2022). Cloud computing and genomic data: Considerations and recommendations. *Nature Reviews Genetics*, 23(3), 173–186. https://doi.org/10.1038/s41576-021-00430-3
41. Schneider, G., & Fechner, U. (2005). Computer-based de novo design of drug-like molecules. *Nature Reviews Drug Discovery*, 4(8), 649–663. https://doi.org/10.1038/nrd1799
42. Schwaller, P., Vaucher, A. C., Laino, T., & Reymond, J. L. (2020). Prediction of chemical reaction yields using deep learning. *Machine Learning: Science and Technology*, 1(4), 045021. https://doi.org/10.1088/2632-2153/aba812
43. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. *Pharmacological Reviews*, 66(1), 334–395. https://doi.org/10.1124/pr.112.007336
44. Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., & Tse, C. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature Medicine*, 19(2), 202–208. https://doi.org/10.1038/nm.3048
45. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
46. van de Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? *Nature Reviews Drug Discovery*, 2(3), 192–204. https://doi.org/10.1038/nrd1032
47. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., & Schwede, T. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. *Nucleic Acids Research*, 46(W1), W296–W303. https://doi.org/10.1093/nar/gky427
48. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., & McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 367(6483), 1260–1263. https://doi.org/10.1126/science.abb2507
49. Wüthrich, K. (2003). NMR studies of structure and function of biological macromolecules (Nobel Lecture). *Journal of Biomolecular NMR*, 27(1), 13–39. https://doi.org/10.1023/A:1025115524017
50. Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., & Tang, Y. (2019). admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics*, 35(6), 1067–1069. https://doi.org/10.1093/bioinformatics/bty707
51. Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S.,

Aladinskiy, V. A., Aladinskaya, A. V., ... & Aspuru-Guzik, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnology*, 37(9), 1038–1040. https://doi.org/10.1038/s41587-019-0224-x

52. Zhou, J., Wang, Y., Wang, J., Tang, Y., & Zhao, W. (2020). Artificial intelligence in drug discovery: Applications and techniques. *Briefings in Bioinformatics*, 21(6), 1676–1693. https://doi.org/10.1093/bib/bbz093
53. Zhu, Y., Yu, D., Wang, X., Dong, W., Liu, X., Zhang, J., & Liang, C. (2020). CRISPR/Cas9-mediated gene editing in cancer immunotherapy. *Theranostics*, 10(20), 8946–8962. https://doi.org/10.7150/thno.46568

HOW TO CITE THIS ARTICLE: Kumar, R., Khan, S.K., Yadav, A.K., Reetu. Integrating Computational and Experimental Approaches in 21st Century Drug Design. J. of Drug Disc. and Health Sci. 2025;2(2):83-90. **DOI:** 10.21590/jddhs.02.02.04